DexCom, Inc. (DXCM) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Wait for pullback to $67.58. At $73.85 the A.R:R is 0.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $67.58 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source key suppliers.
DexCom designs and commercializes continuous glucose monitoring (CGM) systems for diabetes management, with the G7, G7 15 Day, and Stelo (OTC) as current products. Sales of CGM systems are expected to account for substantially all product revenue; reimbursement comes from... Read more
Wait for pullback to $67.58. At $73.85 the A.R:R is 0.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $67.58 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source key suppliers. Chart setup: RSI 55 mid-range, Bollinger mid-band. V9 Gate blocked: R/R 0.2x at spot < 1.5 minimum. Wait for improvement. Score 6.4/10, moderate confidence.
Passes 8/12 gates (positive momentum, clean insider activity, positive momentum, news boost analyst 0.80, earnings proximity 44d clear, semi cycle peak clear, materials cycle peak clear, sector concentration cap sector=healthcare 1/10). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — DexCom, Inc.
Latest news
- NEWS Why DexCom (DXCM) is a top value stock for the long term - MSN — MSN positive
- NEWS DXCM Earnings Preview: DexCom Q2 2026 on April 30 - Meyka — Meyka neutral
- NEWS Vanguard Group Inc. Has $3.26 Billion Stock Holdings in DexCom, Inc. $DXCM - MarketBeat — MarketBeat neutral
- NEWS DexCom (DXCM) Q1 Earnings: What To Expect - StockStory — StockStory neutral
- NEWS DexCom (DXCM) Q1 Earnings: What To Expect - FinancialContent — FinancialContent neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCGM systems10-K Item 1A: 'We expect that sales of our CGM systems will account for substantially all of our product revenue for the foreseeable future.'
- HIGHSuppliersingle- or sole-source key suppliers10-K Item 1A: 'our inability to obtain sufficient quantities of supplies timely and at appropriate quality levels from our single- or sole-source and other key suppliers'
Material Events(8-K, last 90d)
- 2026-03-02Item 5.02LOWKevin Sayer (Executive Chairman) returned from temporary leave effective March 2, 2026, resuming duties. Letter Agreement signed. Mark Foletta resumed duties as Lead Independent Director upon Sayer's return. No departure.SEC filing →
- 2026-02-26Item 5.02LOWAlbert F. ('Rick') Osterloh IV appointed as new Board director effective February 26, 2026, also appointed to Compensation Committee and Technology Committee. No family relationship or related party transactions disclosed.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $67.58. At $73.85 the A.R:R is 0.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $67.58 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source key suppliers. Chart setup: RSI 55 mid-range, Bollinger mid-band. V9 Gate blocked: R/R 0.2x at spot < 1.5 minimum. Wait for improvement. Target $76.69 (+3.8%), stop $61.80 (−19.5%), Setup A.R:R 1.9:1. Score 6.4/10, moderate confidence.
Take-profit target: $76.69 (+13.5% upside). Target $76.69 (+3.8%), stop $61.80 (−19.5%), Setup A.R:R 1.9:1. Stop-loss: $61.80.
Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source key suppliers; Thin upside margin: 3.8%.
DexCom, Inc. trades at a P/E of 32.3 (forward 24.5). TrendMatrix value score: 4.5/10. Verdict: Buy (Wait for Entry).
37 analysts cover DXCM with a consensus score of 4.3/5. Average price target: $85.
What does DexCom, Inc. do?DexCom designs and commercializes continuous glucose monitoring (CGM) systems for diabetes management, with the G7, G7...
DexCom designs and commercializes continuous glucose monitoring (CGM) systems for diabetes management, with the G7, G7 15 Day, and Stelo (OTC) as current products. Sales of CGM systems are expected to account for substantially all product revenue; reimbursement comes from Medicare, Medicaid, and commercial insurers for the G7 and G7 15 Day systems.